Sunday, 3 March 2024

Business News

Walmart likely generated good momentum in Q4, says UBS – TipRanks Financial Blog

Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.

UBS analyst Michael Lasser keeps a Buy rating and $190 price target on Walmart but believes that the company has generated “good momentum” heading into its results. The company’s upcoming Q4 print and its FY24 outlook should provide more optimism on the sustainability of its recent share gains and its future potential, and these attributes should look all the more compelling as several macro uncertainties weigh on retail in the year ahead, namely the uncertain health of the US consumer, food disinflation, and wavering demand for general merchandise, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on WMT:

Click Here to Read the Full Original Article at TipRanks Financial Blog…